Aleksey D. Ryzhkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aleksey D. Ryzhkov has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Alexander S. Krylov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
32 shared publications - E. A. Nickolaeva
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency
15 shared publications - Stepan M. Kaspshik
N.N. Blokhin National Medical Research Center of Oncology
11 shared publications - A. I. Pronin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
9 shared publications - M. E. Bilik
N.N. Blokhin National Medical Research Center of Oncology
9 shared publications - S. N. Prokhorov
N.N. Blokhin National Medical Research Center of Oncology
9 shared publications
Latest Publications
- Open Access
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 30-40
Sequential therapy with radium-223 chloride and 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
Objective : to evaluate the efficacy and safety of sequential treatment with radium-223 chloride (Ra-223) followed by 177 Lu-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice. Material and Methods. This retrospective single-center study included 16 mCRPC patients who received at least 4 Ra-223 injections followed by 177 Lu-PSMA therapy (at least 2 cycles) between 2022 and 2026. The median age was 69.5 years. All patients had bone metastases; 94 % had prior docetaxel treatment. We assessed biochemical response (prostate-specific antigen (PSA) decline >50 %), radiological response using PSMA PET/CT and bone scintigraphy, and toxicity according to CTCAE v5.0. Results. Twelve patients received a full course of Ra-223 (6 injections). Biochemical response to Ra-223 was observed in 2 (12.5 %) patients, radiological response in 5 (31.3 %). After a median interval of 2.2 months, 177 Lu-PSMA therapy was initiated (median 5 cycles). Biochemical response to 177 Lu-PSMA was achieved in 11 (68.8 %) patients, including 7 out of 9 who had progressed on Ra-223. Radiological response was recorded in 9 (56.3 %) patients. Median PSA level decreased from 130.5 to 15.9 ng/mL. Severe (grade 3) hematological toxicity occurred in 2 (12.5 %) patients, xerostomia in 3 (18.8 %). Conclusion. Sequential therapy with Ra-223 and 177 Lu-PSMA demonstrates high efficacy (68.8 % biochemical response rate) and an acceptable safety profile in mCRPC patients, including those with progression on Ra-223, supporting the feasibility of this therapeutic strategy in clinical practice.
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 30-40
Open AccessSequential therapy with radium-223 chloride and 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
Objective : to evaluate the efficacy and safety of sequential treatment with radium-223 chloride (Ra-223) followed by 177 Lu-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice. Material and Methods. This retrospective single-center study included 16 mCRPC patients who received at least 4 Ra-223 injections followed by 177 Lu-PSMA therapy (at least 2 cycles) between 2022 and 2026. The median age was 69.5 years. All patients had bone metastases; 94 % had prior docetaxel treatment. We assessed biochemical response (prostate-specific antigen (PSA) decline >50 %), radiological response using PSMA PET/CT and bone scintigraphy, and toxicity according to CTCAE v5.0. Results. Twelve patients received a full course of Ra-223 (6 injections). Biochemical response to Ra-223 was observed in 2 (12.5 %) patients, radiological response in 5 (31.3 %). After a median interval of 2.2 months, 177 Lu-PSMA therapy was initiated (median 5 cycles). Biochemical response to 177 Lu-PSMA was achieved in 11 (68.8 %) patients, including 7 out of 9 who had progressed on Ra-223. Radiological response was recorded in 9 (56.3 %) patients. Median PSA level decreased from 130.5 to 15.9 ng/mL. Severe (grade 3) hematological toxicity occurred in 2 (12.5 %) patients, xerostomia in 3 (18.8 %). Conclusion. Sequential therapy with Ra-223 and 177 Lu-PSMA demonstrates high efficacy (68.8 % biochemical response rate) and an acceptable safety profile in mCRPC patients, including those with progression on Ra-223, supporting the feasibility of this therapeutic strategy in clinical practice.
- 14 June 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (2)
Van Neck-Odelberg Syndrome. Case Series
Purpose : To demonstrate radiological manifestations of a rare benign disease of childhood. Materials and Methods: The study included 7 cancer patients examined to rule out bone metastases. The sample was collected in 2024 and 2025. All patients underwent bone scans, supplemented by SPECT/CT. Results : In all cases, classic manifestations of the condition described in the literature were observed. Conclusion : Primarily due to its rarity, the syndrome can be challenging to differentiate from other conditions, including malignancies. Raising awareness will help avoid unnecessary treatment and diagnostic interventions.
- 14 June 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (2)
Van Neck-Odelberg Syndrome. Case Series
Purpose : To demonstrate radiological manifestations of a rare benign disease of childhood. Materials and Methods: The study included 7 cancer patients examined to rule out bone metastases. The sample was collected in 2024 and 2025. All patients underwent bone scans, supplemented by SPECT/CT. Results : In all cases, classic manifestations of the condition described in the literature were observed. Conclusion : Primarily due to its rarity, the syndrome can be challenging to differentiate from other conditions, including malignancies. Raising awareness will help avoid unnecessary treatment and diagnostic interventions.
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Standardized Method for Quantitative Assessment of the Efficacy of Bone-Targeted Radionuclide Therapy with Radium-223 Chloride in Patients with Prostate Cancer.
Introduction : Radium-223 (²²³Ra) therapy improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC), but response monitoring is challenging due to the lack of classic PSA response. Standardized assessment methods based on imaging are needed. Objective : To develop and evaluate a comprehensive diagnostic algorithm for quantitative monitoring of the efficacy of ²²³Ra therapy based on SPECT/CT and bone scintigraphy data. Materials and Methods : A prospective single-center study included 114 mCRPC patients who received 2 to 6 injections of ²²³Ra. All patients underwent planar bone scintigraphy with automated Bone Scan Index (aBSI) calculation, quantitative SPECT/CT with standardized uptake value (SUV max , SUV mean ) and percent injected dose (%ID) calculation, PSMA-ligand PET/CT, assessment of biochemical markers (PSA, LDH, ALP) and clinical status. Results : In patients who completed the full course (6 injections, n = 64), a statistically significant decrease in all quantitative parameters was revealed: SUV max (from 51.9 ± 16.4 to 30.5 ± 11.2; p < 0.001), SUV mean (from 2.87 ± 0.63 to 2.43 ± 0.58; p = 0.021), %ID (from 12.4 ± 3.1 to 10.8 ± 2.6; p = 0.037), aBSI (from 2.15 ± 0.38 to 1.70 ± 0.31; p = 0.005), as well as levels of PSA, LDH and ALP. Imaging parameters significantly correlated with ALP levels, pain syndrome, functional status, and the development of hematological toxicity. High baseline SUV mean , %ID, and aBSI values were associated with an increased risk of myelosuppression. Conclusion : Quantitative SPECT/CT parameters (SUV max , SUV mean , %ID) and scintigraphy parameters (aBSI) are objective markers of the efficacy of ²²³Ra therapy, reflecting the dynamics of the metabolic activity of bone metastases and allowing to predict the development of hematological toxicity. A comprehensive multiparameter approach improves the accuracy of treatment response assessment.
- 28 March 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Standardized Method for Quantitative Assessment of the Efficacy of Bone-Targeted Radionuclide Therapy with Radium-223 Chloride in Patients with Prostate Cancer.
Introduction : Radium-223 (²²³Ra) therapy improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC), but response monitoring is challenging due to the lack of classic PSA response. Standardized assessment methods based on imaging are needed. Objective : To develop and evaluate a comprehensive diagnostic algorithm for quantitative monitoring of the efficacy of ²²³Ra therapy based on SPECT/CT and bone scintigraphy data. Materials and Methods : A prospective single-center study included 114 mCRPC patients who received 2 to 6 injections of ²²³Ra. All patients underwent planar bone scintigraphy with automated Bone Scan Index (aBSI) calculation, quantitative SPECT/CT with standardized uptake value (SUV max , SUV mean ) and percent injected dose (%ID) calculation, PSMA-ligand PET/CT, assessment of biochemical markers (PSA, LDH, ALP) and clinical status. Results : In patients who completed the full course (6 injections, n = 64), a statistically significant decrease in all quantitative parameters was revealed: SUV max (from 51.9 ± 16.4 to 30.5 ± 11.2; p < 0.001), SUV mean (from 2.87 ± 0.63 to 2.43 ± 0.58; p = 0.021), %ID (from 12.4 ± 3.1 to 10.8 ± 2.6; p = 0.037), aBSI (from 2.15 ± 0.38 to 1.70 ± 0.31; p = 0.005), as well as levels of PSA, LDH and ALP. Imaging parameters significantly correlated with ALP levels, pain syndrome, functional status, and the development of hematological toxicity. High baseline SUV mean , %ID, and aBSI values were associated with an increased risk of myelosuppression. Conclusion : Quantitative SPECT/CT parameters (SUV max , SUV mean , %ID) and scintigraphy parameters (aBSI) are objective markers of the efficacy of ²²³Ra therapy, reflecting the dynamics of the metabolic activity of bone metastases and allowing to predict the development of hematological toxicity. A comprehensive multiparameter approach improves the accuracy of treatment response assessment.
- Open Access
- 9 November 2025
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 29‑33
Three-phase scintigraphy as an addition to the traditional singlephoton diagnosis of patients with neuroendocrine tumors
Introduction . Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms originating from enterochromaphin cells of the diffuse endocrine system. Nuclear medicine, imaging of somatostatin receptors, plays a leading role in identifying and assessing the status of NET. Purpose . To determine the complex of X-ray and radiological signs characteristic of neuroendocrine tumors and compare them with an immunohistochemical study of expression levels of somatostatin receptors. Materials and methods . The study included 119 patients with NET of various localizations who were examined at the N. N. Blokhin National Research Medical Center of Oncology from 2019 to 2022. There are 75 women and 44 men among them (63 % and 37 %, respectively). The age of the patients ranged from 1 to 84 years (median – 60). Results . When comparing the Grade values depending on the «flash» in a dynamic study, we found statistically significant differences (p=0.010).Conclusions. Clinical and radiological criteria for the qualitative characteristics of dynamic scintigraphy in NET make it possible to predict the effectiveness of treatment and the course of the disease, and the use of 3-phase scintigraphy with 99mTc-tectrotide makes it possible to diagnose a neuroendocrine tumor in 46 % of patients before receiving histological material or when it is impossible to obtain it.
- 9 November 2025
- Published by Alfmed LLC in Medical alphabet
- No. 26,p. 29‑33
Open AccessThree-phase scintigraphy as an addition to the traditional singlephoton diagnosis of patients with neuroendocrine tumors
Introduction . Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms originating from enterochromaphin cells of the diffuse endocrine system. Nuclear medicine, imaging of somatostatin receptors, plays a leading role in identifying and assessing the status of NET. Purpose . To determine the complex of X-ray and radiological signs characteristic of neuroendocrine tumors and compare them with an immunohistochemical study of expression levels of somatostatin receptors. Materials and methods . The study included 119 patients with NET of various localizations who were examined at the N. N. Blokhin National Research Medical Center of Oncology from 2019 to 2022. There are 75 women and 44 men among them (63 % and 37 %, respectively). The age of the patients ranged from 1 to 84 years (median – 60). Results . When comparing the Grade values depending on the «flash» in a dynamic study, we found statistically significant differences (p=0.010).Conclusions. Clinical and radiological criteria for the qualitative characteristics of dynamic scintigraphy in NET make it possible to predict the effectiveness of treatment and the course of the disease, and the use of 3-phase scintigraphy with 99mTc-tectrotide makes it possible to diagnose a neuroendocrine tumor in 46 % of patients before receiving histological material or when it is impossible to obtain it.
- Open Access
- 3 April 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (1) , 36-43
Yuantitative Assessment of the Effectiveness of Radium-223 Chloride Therapy Based on Osteoscintigraphy
Evaluation of the effectiveness of bone metastasis therapy is an important problem in patients with prostate cancer, mainly due to the relationship between bone metastases, survival and quality of life, which necessitates the correct interpretation of treatment response results. The use of additional imaging techniques in clinical practice, along with the assessment of PSA, aims to improve early prognosis of outcome and monitor response to therapy in patients with metastatic CRPC. For effective clinical management of patients receiving Ra-223, radiological response markers are needed to minimize the likelihood of disease progression during therapy and to stratify patients to select subsequent treatment options.Objective: To study the automated bone scanning index (aBSI) as a quantitative radiological assessment of bone scintigraphy results in patients with metastatic castration-resistant prostate cancer (mCRPC) who received systemic radionuclide therapy (RNT) Ra-223.Matreial and Methods: The study included 30 patients who underwent bone scintigraphy before treatment with Ra-223 and aŌer completion of the full course of treatment, laboratory data (PSA, LDH, ALP) obtained before each administration, and the clinical status (Karnovsky index, ECOG) and pain syndrome (VAS) were evaluated. aBSI was obtained at the initial stage and at the end of treatment.Results: The average aBSI level before the start of Ra-223 therapy was 3.5 ц 4.0 (range 0.0ʹ14.7, median 1.9), moderately correlated with PSA (r с 0.482; р с 0.007) and high with alkaline phosphatase (r с 0.710; p ф 0.001). AŌer therapy, aBSI — 3.7 ц 4.8 (range 0.1ʹ19.8, median 1.55) was moderately correlated with alkaline phosphatase aŌer therapy (r с 0.435; р с 0.018). A decrease in the aBSI level was noted in 16/30 (53.3 й). A consistent decrease in LDH and aBSI values in 6/30 (20 й) patients, an increase of 10/30 (30 й). Decrease in both ALP and aBSI in 14/30 (46.7 й) patients, increase in 7/30 (23.3 й), decrease in both PSA and aBSI in 4/30 (13.3 й) patients, increase in 13/30 (43.3 й). A decrease in all parameters was observed in 3/30 (10 й) patients, an increase of 5/30 (16.7 й). An increase in aBSI aŌer completion of therapy was detected in 14/30 (46.7 й), of which 11/14 (78.6 й) were accompanied by an increase in PSA, 4/14 (28.6 й) by an increase in LDH, and 5/14 (35.7 й) by an increase in alkaline phosphatase. Also, in patients who noted an increase in bone pain syndrome, the aBSI increased at the end of therapy, and with a decrease and stabilization, the aBSI decreased (р с 0 . 0 4 7).Conclusion: Both the initial aBSI index and its change after completion of Ra-223 treatment can be used as a radiological marker of response to assess the effectiveness of Ra-223 therapy in patients with mCRPC.
- 3 April 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (1) , 36-43
Open AccessYuantitative Assessment of the Effectiveness of Radium-223 Chloride Therapy Based on Osteoscintigraphy
Evaluation of the effectiveness of bone metastasis therapy is an important problem in patients with prostate cancer, mainly due to the relationship between bone metastases, survival and quality of life, which necessitates the correct interpretation of treatment response results. The use of additional imaging techniques in clinical practice, along with the assessment of PSA, aims to improve early prognosis of outcome and monitor response to therapy in patients with metastatic CRPC. For effective clinical management of patients receiving Ra-223, radiological response markers are needed to minimize the likelihood of disease progression during therapy and to stratify patients to select subsequent treatment options.Objective: To study the automated bone scanning index (aBSI) as a quantitative radiological assessment of bone scintigraphy results in patients with metastatic castration-resistant prostate cancer (mCRPC) who received systemic radionuclide therapy (RNT) Ra-223.Matreial and Methods: The study included 30 patients who underwent bone scintigraphy before treatment with Ra-223 and aŌer completion of the full course of treatment, laboratory data (PSA, LDH, ALP) obtained before each administration, and the clinical status (Karnovsky index, ECOG) and pain syndrome (VAS) were evaluated. aBSI was obtained at the initial stage and at the end of treatment.Results: The average aBSI level before the start of Ra-223 therapy was 3.5 ц 4.0 (range 0.0ʹ14.7, median 1.9), moderately correlated with PSA (r с 0.482; р с 0.007) and high with alkaline phosphatase (r с 0.710; p ф 0.001). AŌer therapy, aBSI — 3.7 ц 4.8 (range 0.1ʹ19.8, median 1.55) was moderately correlated with alkaline phosphatase aŌer therapy (r с 0.435; р с 0.018). A decrease in the aBSI level was noted in 16/30 (53.3 й). A consistent decrease in LDH and aBSI values in 6/30 (20 й) patients, an increase of 10/30 (30 й). Decrease in both ALP and aBSI in 14/30 (46.7 й) patients, increase in 7/30 (23.3 й), decrease in both PSA and aBSI in 4/30 (13.3 й) patients, increase in 13/30 (43.3 й). A decrease in all parameters was observed in 3/30 (10 й) patients, an increase of 5/30 (16.7 й). An increase in aBSI aŌer completion of therapy was detected in 14/30 (46.7 й), of which 11/14 (78.6 й) were accompanied by an increase in PSA, 4/14 (28.6 й) by an increase in LDH, and 5/14 (35.7 й) by an increase in alkaline phosphatase. Also, in patients who noted an increase in bone pain syndrome, the aBSI increased at the end of therapy, and with a decrease and stabilization, the aBSI decreased (р с 0 . 0 4 7).Conclusion: Both the initial aBSI index and its change after completion of Ra-223 treatment can be used as a radiological marker of response to assess the effectiveness of Ra-223 therapy in patients with mCRPC.
- 16 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 49-55
Possibilities of whole body MRI in assessing the prevalence of malignant tumor process
Purpose. To evaluate the capabilities of whole-body MRI based on accelerated acquisition sequences in assessing the extent of malignancy.Material and methods. The study included 30 patients with malignant, solid tumors of various origins and metastatic lesions of various anatomical structures. All patients underwent WB-MRI, based on accelerated data collection sequences, with subsequent clarifying studies, such as CT, PET/ CT, ultrasound to confirm or refute the malignancy of the detected changes.Results. In 14 out of 30 cases, it was possible to identify additional localizations of metastatic lesions, excluding skeletal bones.Conclusion. In modern conditions, WB-MRI makes it possible to collect comprehensive information for staging a tumor disease in a relatively short period of time.
- 16 December 2024
- Published by Alfmed LLC in Medical alphabet
- No. 27,p. 49-55
Possibilities of whole body MRI in assessing the prevalence of malignant tumor process
Purpose. To evaluate the capabilities of whole-body MRI based on accelerated acquisition sequences in assessing the extent of malignancy.Material and methods. The study included 30 patients with malignant, solid tumors of various origins and metastatic lesions of various anatomical structures. All patients underwent WB-MRI, based on accelerated data collection sequences, with subsequent clarifying studies, such as CT, PET/ CT, ultrasound to confirm or refute the malignancy of the detected changes.Results. In 14 out of 30 cases, it was possible to identify additional localizations of metastatic lesions, excluding skeletal bones.Conclusion. In modern conditions, WB-MRI makes it possible to collect comprehensive information for staging a tumor disease in a relatively short period of time.
- Open Access
- 20 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 87-95
Difficulties in the Diagnosis of Neuroendocrine Tumors Metastases. Clinical Case
In this clinical case we analyzed the need for a correct algorithm for examining patients with liver tumors when making a primary diagnosis, thus it significantly affects the prognosis and course of the disease. We demonstrate capabilities of various diagnostic methods in the differential diagnosis of focal liver lesions. Our clinical case confirms the need for optimal routing schemes for patients to specialized centers that have all necessary resources to perform all types of diagnostic methods, including nuclear medicine diagnosis, as well as the presence of a multidisciplinary team of specialists. The article is illustrated with original images of nuclear medicine studies, CT and MRI images.
- 20 September 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (3) , 87-95
Open AccessDifficulties in the Diagnosis of Neuroendocrine Tumors Metastases. Clinical Case
In this clinical case we analyzed the need for a correct algorithm for examining patients with liver tumors when making a primary diagnosis, thus it significantly affects the prognosis and course of the disease. We demonstrate capabilities of various diagnostic methods in the differential diagnosis of focal liver lesions. Our clinical case confirms the need for optimal routing schemes for patients to specialized centers that have all necessary resources to perform all types of diagnostic methods, including nuclear medicine diagnosis, as well as the presence of a multidisciplinary team of specialists. The article is illustrated with original images of nuclear medicine studies, CT and MRI images.
- Open Access
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 74-86
Quantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy
Background. Systemic radionuclide therapy (RNT) with radium-223 was approved for treatment of bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) based on the results of the phase III ALSYMPCA trial. Radium-223 increases overall survival and improves quality of life of the patients. At the moment, there is no unified algorithm for assessing the effectiveness of radium-223 dichloride therapy using modern diagnostic methods, one of which is quantitative single-photon emission computed tomography/computed tomography (SPECT/CT).Aim. To determine the capabilities of quantitative SPECT/CT in assessing the effectiveness of radium-223 dichloride therapy in patients with bone metastases of CRPC.Materials and methods. The study included 30 patients who received a full course (6 injections) of RNT with radium-223, who before and after therapy underwent PET/CT with prostate-specific membrane antigen (PSMA) ligands and skeletal scans, including quantitative SPECT/CT of the whole body; before each RNT cycle, blood parameters, tumor marker prostate-specific antigen, clinical status, and severity of pain were measured. A comparison and correlation analysis of quantitative parameters of the bone-seeking radiopharmaceutical accumulation, biochemical markers, clinical status, and pain syndrome measured using a visual analogue scale, were performed.Results. Comparison of the quantitative characteristics of bone-seeking radiopharmaceutical accumulation in the skeletal bones before and after RNT showed that only the maximal standardized uptake value (SUVmax) decreased significantly in 25 of 30 patients (p = 0.000215). Considering prostate-specific antigen levels, starting from the 3rd course it waspossible to statistically reliably establish further dynamics of changes in this marker (p 0.05). When analyzing groups of patients divided depending on the changes in pain syndrome per the VAS scale, a decrease in SUVmean and pain syndrome was detected in 13 (59.1 %) patients. Without changes in pain syndrome intensity, SUVmean decreased in 9 (40.9 %). The differences in indicators were statistically significant (p = 0.008).Conclusion. There is a tendency towards a decrease in the quantitative indicators of radiopharmaceutical accumulation after systemic RNT with radium-223 dichloride. The relationship between quantitative indicators of the bone-seeking radiopharmaceutical accumulation, laboratory parameters and clinical status is observed. However, each of the analyzed indicators separately does not fully reflect the effectiveness of the therapy.In the future, quantitative SPECT/CT may become more widely used not only for selecting patients for systemic RNT with radium-223 dichloride, but also for assessing its effectiveness since it provides objective view of the distribution pattern of radiopharmaceutical in areas of metastasis and correlates with other assessment methods. It can also become an important prognostic factor in monitoring the condition of patients with mCRPC.
- 15 August 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (2) , 74-86
Open AccessQuantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy
Background. Systemic radionuclide therapy (RNT) with radium-223 was approved for treatment of bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) based on the results of the phase III ALSYMPCA trial. Radium-223 increases overall survival and improves quality of life of the patients. At the moment, there is no unified algorithm for assessing the effectiveness of radium-223 dichloride therapy using modern diagnostic methods, one of which is quantitative single-photon emission computed tomography/computed tomography (SPECT/CT).Aim. To determine the capabilities of quantitative SPECT/CT in assessing the effectiveness of radium-223 dichloride therapy in patients with bone metastases of CRPC.Materials and methods. The study included 30 patients who received a full course (6 injections) of RNT with radium-223, who before and after therapy underwent PET/CT with prostate-specific membrane antigen (PSMA) ligands and skeletal scans, including quantitative SPECT/CT of the whole body; before each RNT cycle, blood parameters, tumor marker prostate-specific antigen, clinical status, and severity of pain were measured. A comparison and correlation analysis of quantitative parameters of the bone-seeking radiopharmaceutical accumulation, biochemical markers, clinical status, and pain syndrome measured using a visual analogue scale, were performed.Results. Comparison of the quantitative characteristics of bone-seeking radiopharmaceutical accumulation in the skeletal bones before and after RNT showed that only the maximal standardized uptake value (SUVmax) decreased significantly in 25 of 30 patients (p = 0.000215). Considering prostate-specific antigen levels, starting from the 3rd course it waspossible to statistically reliably establish further dynamics of changes in this marker (p 0.05). When analyzing groups of patients divided depending on the changes in pain syndrome per the VAS scale, a decrease in SUVmean and pain syndrome was detected in 13 (59.1 %) patients. Without changes in pain syndrome intensity, SUVmean decreased in 9 (40.9 %). The differences in indicators were statistically significant (p = 0.008).Conclusion. There is a tendency towards a decrease in the quantitative indicators of radiopharmaceutical accumulation after systemic RNT with radium-223 dichloride. The relationship between quantitative indicators of the bone-seeking radiopharmaceutical accumulation, laboratory parameters and clinical status is observed. However, each of the analyzed indicators separately does not fully reflect the effectiveness of the therapy.In the future, quantitative SPECT/CT may become more widely used not only for selecting patients for systemic RNT with radium-223 dichloride, but also for assessing its effectiveness since it provides objective view of the distribution pattern of radiopharmaceutical in areas of metastasis and correlates with other assessment methods. It can also become an important prognostic factor in monitoring the condition of patients with mCRPC.
- Open Access
- 13 May 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (1) , 36-43
Comparison of scintigraphy with 123I-MIBG and 99mTc-tectrotyde in patients with tumors of a neurogenic nature
Introduction. Neuroblastoma (NB) is the most common extracranial solid tumor in children; it ranks third in the structure of childhood oncopathology, and in the structure of infant cancer up to 1 year of age, it ranks first. In children over 1 year of age, stages 3–4 are detected in more than 50 % of cases. In 60 % of cases, patients with stage 4 are diagnosed with bone marrow and/or bone involvement. This group of patients has one of the lowest survival rates in oncopediatrics. To carry out primary staging, assess the effectiveness of therapy, monitoring and for theranostic purposes, scintigraphy with 123I-MIBG is most often used. There are also studies demonstrating the diagnostic effectiveness of radionuclide studies of NB with somatostatin analogues, which include 99mTc-tectrotyde. Currently, two diagnostic radiopharmaceutical are registered in the Russian Federation: the “reference” 123I-MIBG, the most commonly used for diagnosing NB, and the potentially useful, but not used 99mTc-tectrotyde.Purpose of the study – to determine the possibility of using 99mTc-tectrotyde as a diagnostic radiopharmaceutical for neurogenic tumors in children and compare the diagnostic capabilities of scintigraphy with 123I-MIBG and 99mTc-tectrotyde.Materials and methods. The study included patients with a morphologically verified diagnosis before treatment: 7 patients diagnosed with NB and 1 with a diagnosis of paraganglioma. All patients underwent two consecutive scintigraphic studies: with 123I-MIBG and with 99mTc-tectrotyde with the minimum possible time interval between them (2–6 days), the sequence did not matter. A quantitative assessment of the accumulation levels of both radiopharmaceuticals was carried out using the SPECT/CT method.Results. Compared with 123I-MIBG, 99mTc-tectrotyde scintigraphy allowed visualization of the primary tumor in 7 out of 8 patients, while all metastases were visible in only 1 out of 3 patients.Conclusion. Our study was the first to compare 123I-MIBG and 99mTc-tectrotyde in the diagnosis of childhood neurogenic tumors before treatment. Scintigraphy with 99mTc-tectrotyde turned out to be applicable for the diagnosis of neurogenic tumors, however, a small sample of patients does not allow us to determine the diagnostic effectiveness and requires further study.
- 13 May 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (1) , 36-43
Open AccessComparison of scintigraphy with 123I-MIBG and 99mTc-tectrotyde in patients with tumors of a neurogenic nature
Introduction. Neuroblastoma (NB) is the most common extracranial solid tumor in children; it ranks third in the structure of childhood oncopathology, and in the structure of infant cancer up to 1 year of age, it ranks first. In children over 1 year of age, stages 3–4 are detected in more than 50 % of cases. In 60 % of cases, patients with stage 4 are diagnosed with bone marrow and/or bone involvement. This group of patients has one of the lowest survival rates in oncopediatrics. To carry out primary staging, assess the effectiveness of therapy, monitoring and for theranostic purposes, scintigraphy with 123I-MIBG is most often used. There are also studies demonstrating the diagnostic effectiveness of radionuclide studies of NB with somatostatin analogues, which include 99mTc-tectrotyde. Currently, two diagnostic radiopharmaceutical are registered in the Russian Federation: the “reference” 123I-MIBG, the most commonly used for diagnosing NB, and the potentially useful, but not used 99mTc-tectrotyde.Purpose of the study – to determine the possibility of using 99mTc-tectrotyde as a diagnostic radiopharmaceutical for neurogenic tumors in children and compare the diagnostic capabilities of scintigraphy with 123I-MIBG and 99mTc-tectrotyde.Materials and methods. The study included patients with a morphologically verified diagnosis before treatment: 7 patients diagnosed with NB and 1 with a diagnosis of paraganglioma. All patients underwent two consecutive scintigraphic studies: with 123I-MIBG and with 99mTc-tectrotyde with the minimum possible time interval between them (2–6 days), the sequence did not matter. A quantitative assessment of the accumulation levels of both radiopharmaceuticals was carried out using the SPECT/CT method.Results. Compared with 123I-MIBG, 99mTc-tectrotyde scintigraphy allowed visualization of the primary tumor in 7 out of 8 patients, while all metastases were visible in only 1 out of 3 patients.Conclusion. Our study was the first to compare 123I-MIBG and 99mTc-tectrotyde in the diagnosis of childhood neurogenic tumors before treatment. Scintigraphy with 99mTc-tectrotyde turned out to be applicable for the diagnosis of neurogenic tumors, however, a small sample of patients does not allow us to determine the diagnostic effectiveness and requires further study.
- Open Access
- 29 March 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (1) , 19-29
Application of Hybrid Radionuclide Imaging Technologies and Radionuclide Therapy in Patients with Osteogenic Sarcoma
Purpose: To demonstrate the capabilities of various hybrid methods for studying the skeletal system in diagnosing the primary focus and metastases of osteosarcoma. To acquaint specialists with the prospects of using radionuclide therapy in the treatment of patients with osteosarcoma.Material and methods: The material consisted of the most demonstrative cases from the clinical practice of the N.N. Blokhin National Medical Research Center of Oncology.Results: The given examples showed the need to involve all possible radionuclide modalities for diagnosis and, especially, monitoring of patients with osteosarcoma for earlier detection of relapses and metastases.Conclusions: The wider use of modern hybrid research methods (SPECT/CT and PET/CT) makes it possible to expand the possibilities for earlier detection of osteosarcoma metastases not only in bones, but also in other organs and tissues.
- 29 March 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (1) , 19-29
Open AccessApplication of Hybrid Radionuclide Imaging Technologies and Radionuclide Therapy in Patients with Osteogenic Sarcoma
Purpose: To demonstrate the capabilities of various hybrid methods for studying the skeletal system in diagnosing the primary focus and metastases of osteosarcoma. To acquaint specialists with the prospects of using radionuclide therapy in the treatment of patients with osteosarcoma.Material and methods: The material consisted of the most demonstrative cases from the clinical practice of the N.N. Blokhin National Medical Research Center of Oncology.Results: The given examples showed the need to involve all possible radionuclide modalities for diagnosis and, especially, monitoring of patients with osteosarcoma for earlier detection of relapses and metastases.Conclusions: The wider use of modern hybrid research methods (SPECT/CT and PET/CT) makes it possible to expand the possibilities for earlier detection of osteosarcoma metastases not only in bones, but also in other organs and tissues.